#USA #New York #Class Action #Nektar Therapeutics #Jonathan Zalevsky

Nektar Therapeutics Under Fire: Securities Fraud Allegations

Overview of the Situation

In a significant development for Nektar Therapeutics (NASDAQ: NKTR), Chief Research and Development Officer Jonathan Zalevsky has been named in a securities fraud lawsuit. The case, initiated by the law firm Levi & Korsinsky, LLP, aims to represent shareholders who acquired stocks between February 26, 2025, and December 15, 2025, and subsequently experienced financial losses. The crux of the allegations revolves around Zalevsky's purported misrepresentation of patient enrollment criteria for a pivotal clinical trial, which resulted in significant stock price drops and investor losses.

Details of the Allegations

Following the revelation that Nektar mistakenly included four ineligible patients in the Phase 2b REZOLVE-AA trial, which was intended to treat alopecia areata, shares plummeted by approximately 7.77%, equating to a loss of $4.14 per share. The complaint asserts that Zalevsky had consistently assured investors—on multiple occasions during earnings calls—that all enrolled patients strictly met specific eligibility requirements, including having severe disease for at least six months.

Specific Instances of Misstatements

1. On March 12, 2025, Zalevsky stated that patients had to present with severe-to-very-severe disease for at least six months to qualify for the trial.
2. During the Q1 earnings call on May 8, 2025, he reiterated these exact criteria.
3. In a November 6, 2025, call, he confirmed that patients who had unstable or diffuse alopecia were excluded from the study.

Despite these assurances, the subsequent investigation disclosed that four patients did not meet these stringent criteria, raising critical questions about the integrity and oversight of the clinical trial.

Executive Responsibility and Financial Incentives

The lawsuit further scrutinizes Zalevsky’s role in the corporate framework, highlighting his personal financial incentives. For instance, it is asserted that his 2024 annual bonus of $431,885 was partially tied to the progress of patient enrollment in the REZOLVE-AA trial. This raises concerns that, under pressure to meet enrollment targets, adherence to rigorous trial protocols may have been compromised. Joseph E. Levi, the attorney representing investors, emphasizes that corporate executives who execute SEC certifications must ensure the accuracy of their disclosures and cannot mislead investors.

Legal Framework: Section 20(a) Claims

The complaint cites Zalevsky as a controlling person under Section 20(a) of the Securities Exchange Act, which suggests he had significant influence over the company's editorial content and public statements regarding the trial. The allegations imply that Zalevsky was privy to crucial information about patient enrollment adherence and failed to disclose this to the public, thereby breaching his duty to shareholders.

Call to Action for Affected Investors

Those who believe they have suffered losses related to this case are encouraged to act swiftly. The deadline to act as a lead plaintiff is May 5, 2026. Investors interested in potential recovery of these losses should contact Joseph E. Levi, Esq. at (212) 363-7500 for further assistance and guidance on navigating this legal landscape.

Conclusion

The unfolding situation at Nektar Therapeutics illustrates the critical importance of transparency and accuracy in clinical trial communications. As this case develops, it highlights the potential ramifications for executives in the biopharmaceutical sector who may misrepresent essential data during the course of their work. Investors are urged to stay informed and vigilant as the legal proceedings reveal more about the conduct of Nektar’s leadership during this critical phase.